((自动化翻译由路透提供，请见免责声明 )) (更新)
11月4日 - ** Viking Therapeutics 股价下跌7.92%至67.15美元，扭转了 盘前涨势
** 该公司在《肥胖周》（ObesityWeek）会议上公布了其试验性口服肥胖症药物VK2735的 (link)。
** 在一项早期试验中，服用 100 毫克剂量药物的患者在 28 天内体重减轻了 8.2
** 分析师说，投资者可能会担心该公司生产该产品的能力
**Viking 公司的数据看起来很有竞争力，但还需要更长时间和更大规模的研究来验证。
** 股价在过去一年里几乎翻了两番
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.